Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. van den Bent MJ, et al. Among authors: nowak ak. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Lancet. 2017. PMID: 28801186 Free PMC article.
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P. Buikhuisen WA, et al. Among authors: nowak ak. Lancet Oncol. 2013 May;14(6):543-51. doi: 10.1016/S1470-2045(13)70125-6. Epub 2013 Apr 12. Lancet Oncol. 2013. PMID: 23583604 Clinical Trial.
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G; CABARET/COGNO investigators; Rosenthal MA. Field KM, et al. Among authors: nowak ak. Neuro Oncol. 2015 Nov;17(11):1504-13. doi: 10.1093/neuonc/nov104. Epub 2015 Jun 30. Neuro Oncol. 2015. PMID: 26130744 Free PMC article. Clinical Trial.
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
Field KM, Phal PM, Fitt G, Goh C, Nowak AK, Rosenthal MA, Simes J, Barnes EH, Sawkins K, Cher LM, Hovey EJ, Wheeler H. Field KM, et al. Among authors: nowak ak. Cancer. 2017 Sep 15;123(18):3576-3582. doi: 10.1002/cncr.30838. Epub 2017 Jul 5. Cancer. 2017. PMID: 28678383 Free article. Clinical Trial.
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.
Field KM, Fitt G, Rosenthal MA, Simes J, Nowak AK, Barnes EH, Sawkins K, Goh C, Moffat BA, Salinas S, Cher L, Wheeler H, Hovey EJ, Phal PM; CABARET/COGNO Investigators. Field KM, et al. Among authors: nowak ak. Asia Pac J Clin Oncol. 2018 Oct;14(5):e359-e365. doi: 10.1111/ajco.12806. Epub 2017 Nov 8. Asia Pac J Clin Oncol. 2018. PMID: 29114999 Clinical Trial.
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. Brandes AA, et al. Among authors: nowak ak. Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28. Oncologist. 2019. PMID: 30266892 Free PMC article. Clinical Trial.
Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.
Hovey EJ, Field KM, Rosenthal MA, Barnes EH, Cher L, Nowak AK, Wheeler H, Sawkins K, Livingstone A, Phal P, Goh C, Simes J; CABARET/COGNO investigators. Hovey EJ, et al. Among authors: nowak ak. Neurooncol Pract. 2017 Sep;4(3):171-181. doi: 10.1093/nop/npw025. Epub 2017 May 25. Neurooncol Pract. 2017. PMID: 31386014 Free PMC article.
266 results